The Effects of the Pneumonia Lung Microenvironment on MSC Function

• Published in: Cells (Basel, Switzerland) Vol. 13; no. 18; p. 1581
• Main Authors: Liu, Lanzhi, Fandiño, Juan, McCarthy, Sean D., Masterson, Claire H., Sallent, Ignacio, Du, Shanshan, Warren, Abigail, Laffey, John G., O’Toole, Daniel
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.09.2024; MDPI
• Subjects: Acute respiratory distress syndrome; Animal models; Animals; Apoptosis; Bacterial pneumonia; Cell culture; Cell Proliferation; Cell surface; Cell therapy; Cellular Microenvironment; Clinical trials; Cytokines; Cytokines - metabolism; Disease Models, Animal; E coli; Escherichia coli; Flow cytometry; Growth factors; Health aspects; Humans; Inflammation; Lung - pathology; lung microenvironment; Lungs; Lymphocytes T; Male; Medical research; mesenchymal stem cell (MSC); Mesenchymal Stem Cell Transplantation - methods; Mesenchymal stem cells; Mesenchymal Stem Cells - metabolism; Pneumonia; Pneumonia - metabolism; Pneumonia - pathology; Pneumonia - therapy; Proteins; R&D; Rats; Rats, Sprague-Dawley; Research & development; Research ethics; Respiratory distress syndrome; Respiratory Distress Syndrome - metabolism; Respiratory Distress Syndrome - pathology; Respiratory Distress Syndrome - therapy; Surface markers; T cells; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; United Kingdom; Ireland; United Kingdom > UK; United States > US; inflammation; mesenchymal stem cell (MSC); lung microenvironment

Background: Despite promise in preclinical models of acute respiratory distress syndrome (ARDS), mesenchymal stem cells (MSC) have failed to translate to therapeutic benefit in clinical trials. The MSC is a live cell medicine and interacts with the patient’s disease state. Here, we explored this int...